NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) will present new data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, from August 28–31, 2026. Three presentations will cover Lp(a) variability, pooled lipid-lowering efficacy of CETP inhibitor obicetrapib, and the relationship between extreme HDL-C levels and mortality.

According to NewAmsterdam, prior Phase 2 and Phase 3 trials of obicetrapib showed statistically significant LDL-C reductions with a placebo-like side effect profile. The Phase 3 PREVAIL cardiovascular outcomes trial, which began in March 2022, completed enrollment in April 2024 with over 9,500 patients.

News Explained

The release also states that NewAmsterdam Pharma has exclusively granted Menarini Group commercialization rights in Europe for obicetrapib, either alone or in a fixed-dose combination with ezetimibe, changing who may commercialize the treatment in that region.

Market Context

The prior -0.47% response to the Q2 2026 earnings update provides context for this presentation anno...

Analysis

The prior -0.47% response to the Q2 2026 earnings update provides context for this presentation announcement. The platform record adds historical sensitivity, while Net Selling insider activity warrants monitoring alongside the scheduled data.

Key Figures

ESC Congress dates: August 28-31, 2026 PREVAIL enrollment: over 9,500 patients PREVAIL commencement: March 2022 +1 more

4 metrics

ESC Congress dates August 28-31, 2026 European Society of Cardiology Congress 2026 in Munich

PREVAIL enrollment over 9,500 patients Phase 3 cardiovascular outcomes trial

PREVAIL commencement March 2022 Phase 3 cardiovascular outcomes trial

PREVAIL enrollment completion April 2024 Phase 3 cardiovascular outcomes trial

Historical Context

5 past events · Latest: Aug 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 06	Inducement grants	Neutral	+1.1%	Equity awards covering options and restricted stock units for three new hires
Aug 05	2Q26 earnings report	Negative	-0.5%	Lower revenue and wider net loss accompanied the second-quarter corporate update
Jul 29	Investor day notice	Neutral	-0.3%	Company scheduled an investor day focused on obicetrapib and Phase 3 programs
Jul 24	CHMP opinion	Positive	-3.0%	European regulator recommended marketing authorization for two obicetrapib products
Jul 02	Inducement grants	Neutral	+0.2%	Company granted options and restricted stock units to four new non-executive hires

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent reactions generally diverged from headline direction, including a -2.98% response to a positive CHMP opinion.

Key Terms

ldl-c, cetp inhibitor, lp(a), monotherapy, +1 more

5 terms

ldl-c medical

"patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol"

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

cetp inhibitor medical

"Pooled On-Treatment Lipid-Lowering Efficacy of the CETP Inhibitor Obicetrapib"

A CETP inhibitor is a medicine that blocks a blood protein responsible for moving cholesterol between different carriers, which typically raises “good” HDL cholesterol and can lower “bad” LDL cholesterol. For investors, these drugs matter because if clinical trials and regulators confirm they reduce heart disease, they can create large new revenue streams for developers; conversely, trial failures or safety concerns can sharply reduce a company’s value, like a promising new tool that must still prove it fixes the problem.

lp(a) medical

"Determinants of Short Term Lp(a) Variability in Phase 3 Obicetrapib Trials"

Lp(a), or lipoprotein(a), is a blood particle that carries cholesterol and a specific protein; think of it as a delivery truck that can drop off harmful cargo along artery walls. High Lp(a) levels are linked to increased risk of heart disease and stroke, so changes in testing, treatments, or clinical results for Lp(a) can affect healthcare costs, drug prospects, and investor expectations for companies working on cardiovascular diagnostics or therapies.

monotherapy medical

"evaluating obicetrapib as monotherapy or combination therapy"

Monotherapy is a treatment approach that uses only one type of medicine or therapy to address a condition, instead of combining multiple options. For investors, understanding monotherapy matters because it can influence a company's development strategy, risk profile, and potential market size, especially if the single-treatment approach proves effective or faces limitations compared to combination therapies.

fixed-dose combination medical

"as part of a fixed-dose combination with ezetimibe"

A fixed-dose combination is a single medication that contains two or more active drugs combined in set proportions, like a combo meal that packages complementary items into one order. For investors it matters because such products can improve patient convenience and adherence, streamline manufacturing and marketing, and create distinct regulatory and patent opportunities or risks that affect a drug’s market size, pricing power, and long-term revenue potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31, 2026 in Munich, Germany.

Presentation details are as follows:

Title: Determinants of Short Term Lp(a) Variability in Phase 3 Obicetrapib Trials
Session Title: Novel Lipid Lowering Therapies for Residual Risk
Session Number: 3579
Moderated Poster Presentation Date and Time: Friday, August 28, 2026 at 10:15-11:00 CET
Location: Station 2, Research Gallery Hall A1
Presenters: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma

Title: Pooled On-Treatment Lipid-Lowering Efficacy of the CETP Inhibitor Obicetrapib in Phase III Trials
Session Title: Lipid Lowering and Cardiovascular Outcomes
Session Number: 3582
Moderated Poster Presentation Date and Time: Sunday, August 30, 2026 at 10:15-11:00 CET
Location: Station 2, Research Gallery Hall A1
Presenter: Mathijs A.C. de Kleer

Title: Extreme HDL-C Associated Increased Mortality is Explained by Confounding Due to Progressively Increasing Alcohol-Induced Multisystem Morbidity
Session Title: Lipids and Myocardial Infarction
Session Number: 3102
Oral Presentation Date and Time: Monday, August 31, 2026 at 12:30-12:40 CET
Location: Science Box 5, Research Gateway Hall A1
Presenter: Brian A. Ference, M.D., MPhil, FACC, FESC

About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact

Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact

Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com

Investor Contact

Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

What ESC Congress 2026 presentations will NewAmsterdam Pharma (NAMS) deliver on obicetrapib?

NewAmsterdam will deliver three ESC 2026 presentations focused on obicetrapib and lipid biology. According to NewAmsterdam, topics include short-term Lp(a) variability, pooled on-treatment lipid-lowering efficacy of CETP inhibitor obicetrapib in Phase III trials, and how extreme HDL-C relates to increased mortality.

When and where will NewAmsterdam Pharma (NAMS) present obicetrapib data at ESC Congress 2026?

NewAmsterdam will present obicetrapib data at ESC Congress 2026 from August 28–31 in Munich. According to NewAmsterdam, moderated poster sessions occur August 28 and 30 in Research Gallery Hall A1, and an oral presentation is scheduled August 31 in Science Box 5, Research Gateway Hall A1.

What do existing trials show about obicetrapib’s LDL-C lowering for NewAmsterdam Pharma (NAMS)?

Existing trials show statistically significant LDL-C reductions with obicetrapib and placebo-like side effects. According to NewAmsterdam, multiple Phase 2 and Phase 3 studies, including ROSE2, TULIP, BROOKLYN, BROADWAY, TANDEM and others, observed LDL-lowering efficacy alongside a side effect profile similar to placebo.

What is the PREVAIL cardiovascular outcomes trial mentioned by NewAmsterdam Pharma (NAMS)?

PREVAIL is a Phase 3 cardiovascular outcomes trial evaluating obicetrapib’s impact on major adverse cardiovascular events. According to NewAmsterdam, PREVAIL began in March 2022, completed enrollment in April 2024, and randomized over 9,500 patients to assess obicetrapib in at-risk cardiovascular disease populations.

Who holds European commercialization rights for obicetrapib developed by NewAmsterdam Pharma (NAMS)?

The Menarini Group holds exclusive European commercialization rights for obicetrapib. According to NewAmsterdam, these rights cover obicetrapib in Europe both as monotherapy and as a fixed-dose combination with ezetimibe, supporting potential future market access if clinical development and regulatory processes are successful.